The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Mantle cell lymphoma: initial report from the North American Mantle Cell Lymphoma Consortium.
 
Kai Fu
No Relationships to Disclose
 
Guohua Yu
No Relationships to Disclose
 
Chengfeng Bi
No Relationships to Disclose
 
Hongxia Cheng
No Relationships to Disclose
 
Lynette Smith
No Relationships to Disclose
 
Ji Yuan
No Relationships to Disclose
 
Hina Naushad
No Relationships to Disclose
 
Brian K. Link
Consulting or Advisory Role - Abbvie; Genentech/Roche; Karyopharm Therapeutics
Research Funding - Pharmacyclics/Janssen (Inst)
Travel, Accommodations, Expenses - Genentech/Roche
 
Craig R. Nichols
No Relationships to Disclose
 
Paul M. Barr
Consulting or Advisory Role - Abbvie; AstraZeneca; Celgene; Genentech; Infinity Pharmaceuticals; Janssen; Merck; MorphoSys; Novartis; Pharmacyclics; Seagen; TG Therapeutics
Research Funding - AstraZeneca (Inst); Pharmacyclics (Inst)
 
Brad S. Kahl
Consulting or Advisory Role - Abbvie; Acerta Pharma; ADC Therapeutics; AstraZeneca; Bayer; BeiGene; Celgene; Genentech; Janssen; Juno Therapeutics; Kite/Gilead; MEI Pharma; MorphoSys; Pharmacyclics; Pharmacyclics; Roche; TG Therapeutics
Research Funding - Acerta Pharma (Inst); ADC Therapeutics (Inst); Celgene (Inst); Genentech (Inst)
Travel, Accommodations, Expenses - Abbvie; Celgene; Genentech/Roche; Juno Therapeutics; Millennium; Seagen
 
Douglas Stewart
No Relationships to Disclose
 
Stefan K Barta
No Relationships to Disclose
 
Anne Beaven
No Relationships to Disclose
 
Ranjana H. Advani
Honoraria - Takeda
Consulting or Advisory Role - AstraZeneca; Bayer; Celgene; Cell Medica; Genentech/Roche; Gilead Sciences; Kite, a Gilead company; Kyowa Hakko Kirin; Portola Pharmaceuticals; Sanofi; Seagen; Takeda
Research Funding - Agensys (Inst); Celgene (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Infinity Pharmaceuticals (Inst); Janssen (Inst); Kura Oncology (Inst); Merck (Inst); Millennium (Inst); Pharmacyclics (Inst); Regeneron (Inst); Seagen (Inst)
 
Peter Martin
Consulting or Advisory Role - Bayer; BeiGene; Celgene; Cellectar; I-Mab; Janssen; Karyopharm Therapeutics; Karyopharm Therapeutics; Kite, a Gilead company; MorphoSys; Sandoz; TeneoBio
Research Funding - Karyopharm Therapeutics (Inst)
Travel, Accommodations, Expenses - Janssen
 
Timothy Greiner
No Relationships to Disclose
 
Dennis Weisenburger
No Relationships to Disclose
 
James O. Armitage
Leadership - Tesaro
Stock and Other Ownership Interests - Tesaro
Consulting or Advisory Role - Ascentage Pharma; Conatus; Lundbeck; Oncology Analytics; Partner Therapeutics; Samus Therapeutics; Union Pacific
 
Julie Vose
Honoraria - Abbvie; Acerta Pharma/AstraZeneca; Epizyme; Janssen Scientific Affairs; Kite/Gilead; Legend Biotech; Miltenyi Biotec; Novartis; Vaniam Group; Verastem
Consulting or Advisory Role - Bio Connections
Research Funding - Acerta Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Incyte (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); Novartis (Inst); Seagen (Inst)